FIELD: biotechnology.
SUBSTANCE: present invention relates to antibodies specifically binding to thymic stromal lymphopoietin (TSLP), and can be used in medicine for treating an inflammatory disease, associated with TSLP, selected from asthma, chronic obstructive pulmonary disease, allergic rhinitis, allergic rhinosinusitis, allergic conjunctivitis, eosinophilic oesophagitis and atopic dermatitis. Antibodies and their antigen-binding fragments, containing their compositions, methods of their application and production are offered.
EFFECT: invention enables to obtain an antibody which binds human TSLP with a dissociation constant (KD) of less than 10 pM.
50 cl, 12 dwg, 14 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES BINDING TO 4-1BB | 2011 |
|
RU2551963C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| PROTEASE-ACTIVATED T-CELL BINDING BISPECIFIC MOLECULES | 2017 |
|
RU2830288C2 |
| BINDING MOLECULES INDUCING CELLULAR ACTIVATION | 2019 |
|
RU2770620C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| ANTI-TSLP ANTIBODY AND USE THEREOF | 2020 |
|
RU2834227C1 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
